Precigen Reports Strong Demand for New Rare Disease Drug

Biotech company expects over $18 million in first quarter revenue as it plans expansion into pediatrics and Europe.

Apr. 7, 2026 at 1:16pm

Got story updates? Submit your updates here. ›

An abstract, ghostly X-ray image revealing the delicate internal structure of human lungs, conceptually representing the rare respiratory condition targeted by Precigen's new drug.Precigen's new drug for a rare respiratory disease aims to improve quality of life for patients through an innovative treatment approach.Germantown Today

Precigen Inc., a commercial-stage biopharmaceutical company, has reported robust uptake of its newly approved drug for a rare respiratory disease. The company expects to generate over $18 million in first quarter revenue and is planning to expand the drug's use to pediatric patients as well as seek approval in Europe.

Why it matters

The successful launch of Precigen's new drug for this rare respiratory condition represents an important advancement in treatment options for patients. The strong initial demand and Precigen's plans for further expansion highlight the potential impact this therapy could have in improving quality of life for those affected by this rare disease.

The details

Precigen's new drug received early and full approval for use in treating the rare respiratory disease. In the short time since launch, the company reports seeing "robust uptake" of the new standard-of-care first-line treatment. Precigen is now planning to expand the drug's use to pediatric patients and is also working towards securing European regulatory approval.

  • Precigen's new drug received early and full approval in recent months.
  • Precigen expects to generate over $18 million in first quarter 2026 revenue from the new drug.

The players

Precigen Inc.

A commercial-stage biopharmaceutical company developing precision medicines to improve the quality of life for patients.

Got photos? Submit your photos here. ›

What’s next

Precigen plans to expand use of the new drug to pediatric patients and is also working towards securing regulatory approval in Europe.

The takeaway

Precigen's successful launch of its new rare respiratory disease drug highlights the potential for innovative therapies to make a meaningful impact on patient lives. The company's plans for further expansion demonstrate its commitment to increasing access and improving outcomes for those affected by this rare condition.